|
Market Closed -
Euronext Paris
11:55:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.3215 EUR | -1.08% |
|
-3.89% | +7.89% |
| 09-16 | Nicox to present NCX 470 data at a conference |  |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
| Market Cap | 28.33M 31.89M 26.45M 24.1M 45.46M 3.07B 45.88M 320M 124M 1.57B 120M 117M 5.03B | P/E 2026 * |
-6.43x | P/E 2027 * | 16.1x |
|---|---|---|---|---|---|
| Enterprise Value | 28.33M 31.89M 26.45M 24.1M 45.46M 3.07B 45.88M 320M 124M 1.57B 120M 117M 5.03B | EV / Sales 2026 * |
9.44x | EV / Sales 2027 * | 2.83x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALCOX | Real-time | |
CBOE
| COXp | Real-time | |
|
Deutsche Boerse AG
| NXOA | Delayed | |
|
CBOE
| 0RCQ | Real-time | |
|
Börse Stuttgart
| NXOA | Delayed | |
|
Boerse Muenchen
| NXOA | Real-time |
| 1 day | -1.08% | ||
| 1 week | -3.89% | ||
| Current month | -3.74% | ||
| 1 month | -16.38% | ||
| 3 months | -15.28% | ||
| 6 months | -21.20% | ||
| Current year | +7.89% |
| 1 week | 0.32 |  | 0.34 |
| 1 month | 0.32 | | 0.39 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.45 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 2024-02-27 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 2014-12-31 |
Emmet Purtill
PRN | Corporate Officer/Principal | - | 2005-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 2024-04-07 |
Damian Marron
CHM | Chairman | 64 | 2024-07-15 |
Marc Bozec
BRD | Director/Board Member | - | 2024-07-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/29/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 2/16/21 | Exercice | Chief Executive Officer | 10,000 | 0.0270% | ||
| 2/1/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.08% | -3.89% | -10.94% | -19.83% | 31.89M | |
| -0.61% | -3.43% | +39.40% | +112.31% | 1,019B | |
| -1.02% | -5.60% | +37.67% | +65.02% | 617B | |
| +1.11% | -0.58% | +11.10% | +77.28% | 464B | |
| +0.34% | -3.01% | +61.21% | +40.71% | 356B | |
| -0.95% | -4.05% | +21.60% | +39.37% | 333B | |
| -1.46% | -2.89% | +11.84% | +24.60% | 267B | |
| -1.35% | -5.43% | -4.69% | +8.40% | 244B | |
| -1.04% | -2.79% | +35.52% | +51.34% | 218B | |
| -1.87% | -4.10% | +30.92% | +95.33% | 179B | |
| Average | -0.32% | -3.44% | +23.36% | +49.45% | 369.72B | |
| Weighted average by Cap. | +0.42% | -3.33% | +30.52% | +68.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.38M 2.8M 2.55M 4.81M 325M 4.86M 33.89M 13.13M 166M 12.68M 12.4M 533M | 10M 11.25M 9.33M 8.51M 16.04M 1.08B 16.19M 113M 43.77M 553M 42.26M 41.34M 1.78B |
| Net income | -5M -5.63M -4.67M -4.25M -8.02M -541M -8.1M -56.48M -21.88M -277M -21.13M -20.67M -888M | 2M 2.25M 1.87M 1.7M 3.21M 216M 3.24M 22.59M 8.75M 111M 8.45M 8.27M 355M |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | €0.3215 | -1.08% | 280,187 |
| 26-10-01 | €0.3250 | -2.69% | 114,849 |
| 26-09-30 | €0.3340 | -1.76% | 210,549 |
| 26-09-29 | €0.3400 | +1.64% | 141,180 |
| 26-09-28 | €0.3345 | 0.00% | 44,057 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3215EUR
Average target price
1.000EUR
Spread / Average Target
+211.04%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
